Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | CTSL | P07711 | 5/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724195 | 0.92 | SYK (0.52) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL5724348 | 0.89 | SYK (0.57) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL5724356 | 0.89 | SYK (0.49) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL144788 | 0.89 | SYK (0.45) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL261847 | 0.88 | SYK (0.48) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL29654501 | 0.88 | CTRB1 (0.59) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL263992 | 0.87 | SYK (0.47) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL5724014 | 0.86 | ATM (0.50) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL262927 | 0.86 | SYK (0.47) | CTSKCTSSCTSLCTSBSYK | |
| SCHEMBL263531 | 0.86 | SYK (0.47) | CTSKCTSSCTSLCTSBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | CTSK 3012/4885CTSS 3088/4885CTSL 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.